We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,103

Australian High Court confirms that late applications for pharmaceutical patent term extensions may be granted in Australia
  • DLA Piper LLP
  • Australia
  • May 6 2015

Pharmaceutical patent term extension regimes are of critical importance to innovators in the pharmaceutical industry, for whom an ability to exploit


Could the courts compel prescribers and dispensers of medicines to help big pharma fight generics?
  • Watermark Patent & Trade Marks Attorneys
  • Australia, United Kingdom
  • May 6 2015

A recent UK court ruling broke new ground in ordering an official health body to issue guidelines on prescribing a generic drug. Could the same thing


A myriad of problems and opportunities a comparison of the patentability of isolated nucleic acid in the United States and Australia
  • DLA Piper LLP
  • Australia, USA
  • May 6 2015

Due to the inherent nature of the technologies that underpin it, the biotechnology industry has faced challenges worldwide in relation to precisely


Costs of patent amendment application not immutable; opponent ordered to pay substantial legal costs
  • Davies Collison Cave
  • Australia
  • May 4 2015

Departing from the near 'immutable rule' that the amending party pay any other party's legal costs of the amendment


Federal Court awards additional damages for patent infringement for the first time
  • Davies Collison Cave
  • Australia
  • April 30 2015

The Federal Court has awarded additional damages under section 122(1A) of the Patents Act 1990 (Cth) as well as substantial compensatory


Damages recovery by the Commonwealth pursuant to the “usual undertakings”
  • Davies Collison Cave
  • Australia
  • April 29 2015

A recent procedural decision by Nicholas J in the Federal Court provides an interesting snapshot of the issues involved in the recovery of damages by


Journal 2015 January to March for overseas readers
  • Watermark Patent & Trade Marks Attorneys
  • Australia, New Zealand
  • April 7 2015

The question in Regency Media v MPEG LA was whether s.145 permitted the licensee to terminate a licence to multiple patents upon the expiry of some


IP in depth: patentable biotechnology a comparative analysis of key markets
  • Fisher Adams Kelly
  • Australia, European Union, New Zealand, USA
  • March 31 2015

There is extraordinary complexity and optimization underlying even comparatively 'simple' organisms. These powerful biological products and processes


When 5 federal court judges are just not enough
  • Spruson & Ferguson
  • Australia
  • March 31 2015

In 2013 and 2014, the Federal Court of Australia took the unprecedented step of sitting 5 Judges (instead of 3) to hear the Appeals in two separate


Permissible conduct for owners of an expiring patent were Pfizer's actions a LEAP too far?
  • Addisons
  • Australia
  • March 31 2015

In the recent high profile case, ACCC v Pfizer (Pfizer), Justice Flick held that Pfizer, in making commercial offers to maintain the sale of its